Martinez et al., found higher levels of EGFR in COVID-19 individuals vs. community associated pneumonia subjects (19) and osimertinib, a well-known EGFR antagonist, showed in vitro anti-SARS-CoV-2 action (22) and prevented the virus cytopathic effect (23). This evidence concerns the gene EGFR and pneumonia.